Business Context and Reporting Period
This Form 8-K filing by Immunic, Inc. (IMUX) reports a corporate governance event dated October 11, 2019. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters.
Material Changes
The primary material change is the appointment of Tamar Howson to the Board of Directors, effective October 11, 2019. She serves as a Class II director with a term expiring at the 2022 annual meeting of stockholders.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of the director appointment and associated compensation:
- Equity Grant: Ms. Howson received an option to purchase 29,959 shares of common stock.
- Vesting Schedule: 9,986 shares vest monthly over one year; 19,973 shares vest monthly over three years.
- Exercise Price: $9.54 per share, based on the closing price on the grant date.
- Indemnification: A standard director indemnification agreement was executed.
- Conflicts: No material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Confirm the effective date of the board appointment (October 11, 2019).
- Verify the total number of shares granted (29,959) and the specific vesting tranches.
- Check the exercise price ($9.54) against the market price on the grant date.
- Review the director's term expiration (2022 annual meeting).